---
run_id: halo-evidence-vs-diagnosis-validation-v10-generic-advice-prompted-06
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
model_condition: generic_advice_prompted
run_number: 6
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 1024
seed: 605
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 372fe6128e2e633706cc66d44caf0e7dfaf2bba60181854165887aa7ed453ea9
condition_packet_sha256: 372fe6128e2e633706cc66d44caf0e7dfaf2bba60181854165887aa7ed453ea9
output_file: model-outputs/generic_advice_prompted-06.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 06)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v10-v1`, condition `generic_advice_prompted`, run 6 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 605, on the frozen condition packet.

## Output

I recommend that you commit to the **Claim File Review**.

### Reasoning and Tradeoffs
You are currently facing a "false positive" signal. Your financial metrics (expansion bookings) are being driven by pricing incentives and sales narratives, not necessarily product value. Your usage metrics (39% increase) are being skewed by managers performing audits, which is a different use case than the intended front-line productivity.

The core risk is that DraftPath is a "demo product"—it looks impressive to executives and managers, but it fails the "last mile" of the adjuster's workflow. The evidence in health-liability (abandonment due to lack of explainability) suggests a fundamental gap between the tool's output and the user's professional requirements.

Here is why I chose the Claim File Review over the other options:

*   **Against Scaling Broadly:** This is reckless. You have evidence of "invisible churn" (regional carriers) and a lack of stickiness among front-line users. Scaling now would likely accelerate churn once the bundle pricing expires.
*   **Against the Usage Quality Sprint:** Analytics can tell you *that* a user stopped using a feature, but it cannot tell you *why*. In a complex B2B workflow, "return rates" are vanity metrics if the users returning are only managers. You don't have a tracking problem; you have a value-proposition problem.
*   **Against the Commercial Cleanroom:** This is too late and too risky. With the budget locking in 12 days, you cannot afford to handicap your sales team's ability to close renewals based on a hypothesis. You need to know if the product works before you test how to price it.
*   **Against Narrowing to Health-Liability:** This is a premature pivot. You don't yet know if the "explainability" issue is a universal flaw in DraftPath or a specific regulatory hurdle for health-liability.

The **Claim File Review** is the only option that provides "ground truth." By seeing exactly where suggestions were overridden or rewritten, you move from guessing based on dashboards to knowing why the product is failing the adjuster. This allows you to fix the core utility before committing next year's budget to a flawed version of the tool.

### The Strongest Reason Against This Recommendation
The Claim File Review is slow and qualitative. It provides a "snapshot" rather than a continuous stream of data. While the CEO and Board are currently riding a high from a strong quarter, recommending a manual audit instead of "scaling the winner" may be perceived as a lack of momentum or an overly cautious academic exercise. You risk losing the political capital associated with the "commercially disciplined" label if you cannot translate these qualitative findings into a rapid product iteration.

### Evidence That Would Change My Mind
I would switch my recommendation to the **Commercial Cleanroom** if you discovered that the "invisible churn" from regional carriers was not caused by product failure, but by a specific pricing misalignment (e.g., they love the tool but find the bundle price structure incompatible with their procurement rules). If the product is actually delivering value and the friction is purely commercial, then validating the pricing model becomes the urgent priority.
